The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Drug—target network
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Network biology: understanding the cell's functional organization
Barabási, A.-L., & Oltvai, Z. N. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1272 · Cited by 7,903
Self-citationLethality and centrality in protein networks
Jeong, H., Mason, S. P., Barabási, A.-L., & Oltvai, Z. N. (2001) · Nature · doi:10.1038/35075138 · Cited by 5,287
Self-citationDrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
From molecular to modular cell biology.
Hartwell, L. H., Hopfield, J. J., Leibler, S., & Murray, A. W. (1999) · Nature · doi:10.1038/35011540 · Cited by 3,632
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders
Hamosh, A. (2004) · Nucleic Acids Research · doi:10.1093/nar/gki033 · Cited by 3,420
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Goh, K.-I., Cusick, M. E., Valle, D., Childs, B., Vidal, M., & Barabási, A.-L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701361104 · Cited by 3,242
Self-citationA census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184
Transcriptional Regulatory Networks in Saccharomyces cerevisiae
Lee, T. I., Rinaldi, N. J., Robert, F., Odom, D. T., Bar-Joseph, Z., Gerber, G. K., Hannett, N. M., Harbison, C. T., Thompson, C. M., Simon, I., et al. (2002) · Science · doi:10.1126/science.1075090 · Cited by 2,956
Towards a proteome-scale map of the human protein–protein interaction network
Rual, J.-F., Venkatesan, K., Hao, T., Hirozane-Kishikawa, T., Dricot, A., Li, N., Berriz, G. F., Gibbons, F. D., Dreze, M., Ayivi-Guedehoussou, N., et al. (2005) · Nature · doi:10.1038/nature04209 · Cited by 2,933
Self-citationA Human Protein-Protein Interaction Network: A Resource for Annotating the Proteome
Stelzl, U., Worm, U., Lalowski, M., Haenig, C., Brembeck, F. H., Goehler, H., Stroedicke, M., Zenkner, M., Schoenherr, A., Koeppen, S., et al. (2005) · Cell · doi:10.1016/j.cell.2005.08.029 · Cited by 2,387
Scientific collaboration networks. I. Network construction and fundamental results
Newman, M. E. J. (2001) · Physical Review E · doi:10.1103/physreve.64.016131 · Cited by 2,076
Evidence for dynamically organized modularity in the yeast protein–protein interaction network
Han, J.-D. J., Bertin, N., Hao, T., Goldberg, D. S., Berriz, G. F., Zhang, L. V., Dupuy, D., Walhout, A. J. M., Cusick, M. E., Roth, F. P., et al. (2004) · Nature · doi:10.1038/nature02555 · Cited by 1,798
Self-citationGlivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
The small world inside large metabolic networks
Wagner, A., & Fell, D. A. (2001) · Proceedings of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rspb.2001.1711 · Cited by 981
Drugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
Global mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 811
Structure and evolution of transcriptional regulatory networks
Babu, M. M., Luscombe, N. M., Aravind, L., Gerstein, M., & Teichmann, S. A. (2004) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2004.05.004 · Cited by 763
Systems biology in drug discovery
Butcher, E. C., Berg, E. L., & Kunkel, E. J. (2004) · Nature Biotechnology · doi:10.1038/nbt1017 · Cited by 605
Can we rationally design promiscuous drugs?
HOPKINS, A., MASON, J., & OVERINGTON, J. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.01.013 · Cited by 469
The druggable genome: an update
Russ, A. P., & Lampel, S. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03666-4 · Cited by 424
Dissecting Human Disease in the Postgenomic Era
Peltonen, L., & McKusick, V. A. (2001) · Science · doi:10.1126/science.291.5507.1224 · Cited by 415
Jimenez-Sanchez, G., Childs, B., & Valle, D. (2001) · Nature · doi:10.1038/35057050 · Cited by 379
The Mouse Genome Database (MGD): from genes to mice--a community resource for mouse biology
Eppig, J. T. (2004) · Nucleic Acids Research · doi:10.1093/nar/gki113 · Cited by 277
Ge, X., Yamamoto, S., Tsutsumi, S., Midorikawa, Y., Ihara, S., Wang, S. M., & Aburatani, H. (2005) · Genomics · doi:10.1016/j.ygeno.2005.04.008 · Cited by 248
Rescuing drug discovery: in vivo systems pathology and systems pharmacology
van der Greef, J., & McBurney, R. N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1904 · Cited by 209
Promiscuous drugs compared to selective drugs (promiscuity can be a virtue)
Mencher, S. K., & Wang, L. G. (2005) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-5-3 · Cited by 206
Strategic trends in the drug industry
Drews, J. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02690-4 · Cited by 165
A brief history of novel drug discovery technologies
Gershell, L. J., & Atkins, J. H. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1064 · Cited by 129
Vidal, M. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.02.030 · Cited by 105
Self-citationFulfilling the promise: drug discovery in the post-genomic era
Chanda, S. K., & Caldwell, J. S. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02595-3 · Cited by 104
Pharmacophylogenomics: genes, evolution and drug targets
Searls, D. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1152 · Cited by 91
Topology, tinkering and evolution of the human transcription factor network
Rodríguez‐Caso, C., Medina, M. Á., & Solé, R. V. (2005) · FEBS Journal · doi:10.1111/j.1742-4658.2005.05041.x · Cited by 67
Emergent behavior of growing knowledge about molecular interactions
Cokol, M., Iossifov, I. H., Weinreb, C., & Rzhetsky, A. (2005) · Nature Biotechnology · doi:10.1038/nbt1005-1243 · Cited by 62
Research works printed but not linked: 1
- Lindpaintner, K. The impact of pharmacogenetics and pharmacogenomics on drug discovery. Nat. Rev. Drug Discov. 1, 463–469 (2002). · doi:10.1038/nrd823
Cited by
Network medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034
Self-citationNetwork pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Designing antimicrobial peptides: form follows function
Fjell, C. D., Hiss, J. A., Hancock, R. E. W., & Schneider, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3591 · Cited by 2,035
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Hopkins, A. L. (2007) · Nature Biotechnology · doi:10.1038/nbt1007-1110 · Cited by 1,242
Metadata
- Authors
- Yıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M.
- Venue
- Nature Biotechnology
- Published
- 2007-10
- Volume
- 25
- Issue
- 10
- Pages
- 1119-1126
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W1544009106
- Cited by
- 1,708
- References
- 36
- FWCI
- 83.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.